Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an epithelial cytokine involved in the initiation and persistence of airway inflammation.
Review the December 2021 notable drug approvals.
Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Researchers examined health disparities in the duration of asthma exacerbations in patients post-COVID-19.
A survey of allergists in North America and Europe explored how clinician attitudes towards cannabis affected discussions with patients regarding cannabis.
In children with asthma, is excess weight linked to dysanapsis and PAI — and how do all 3 factors affect the risk of uncontrolled asthma?
Asthma control as measured by AIRQ may predict 12-month HRQoL, according to research reported at the 2021 ACAAI Annual Scientific Meeting.
A post hoc analysis of the QUEST trial assessed clinical remission in patients with moderate-to-severe asthma after 24 and 52 weeks of dupilumab treatment.
CHRONICLE trial findings offer a glimpse of the real-world outcomes of patients using benralizumab for severe asthma over a years’ time.
Research presented at ACAAI 2021 evaluated the efficacy of different biologic therapies in controlling asthma exacerbations in patients with varying BECs.
